Single-Dose Islatravir in Moderate Hepatic Impairment (MK-8591-030)
Status:
Completed
Trial end date:
2021-09-13
Target enrollment:
Participant gender:
Summary
This is an open-label, single-dose study of the plasma pharmacokinetics (PK), safety, and
tolerability of islatravir (ISL, MK-8591), and the intracellular PK of ISL triphosphate
(ISL-TP) in male and female adult participants with moderate hepatic impairment and in
healthy matched control participants.